Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

GenSciences Raises $124 Million for New Drug Development

publication date: Mar 4, 2021

GenSciences, a commercial-stage Changchun drug company, has raised over $124 million in its series A and B rounds, the company announced. GenSci is a wholly owned subsidiary of Changchun High-Tech Industry, which was started as a construction company, but narrowed its focus to life science. Its portfolio includes genetically engineered pharmaceuticals, biological vaccines and modern traditional Chinese medicine. In November 2020, GenSci in-licensed China rights to ready-to-use subcutaneous depot formulations for a prostate cancer therapy from Taiwan's Foresee Pharma. More details....

Stock Symbol: (SHZ: 000661)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021